Candel Therapeutics Inc. Company Profile
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 9.94 0.00%
Candel Therapeutics at a glance
Candel Therapeutics Inc. (NASDAQ: CADL) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Needham, MA. Candel Therapeutics is led by Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. and employs about 55 people. The company's shares have traded publicly since 2021.
At a market capitalization of $751.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001841387, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Candel Therapeutics do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Candel Therapeutics Inc.
- Ticker
- NASDAQ: CADL
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
- Employees
- 55
- Headquarters
- 117 Kendrick Street, Needham, MA, United States
- Phone
- 617 916 5445
- Website
- candeltx.com
- IPO year
- 2021
- Market cap
- $751.41M
- SEC CIK
- 0001841387
- Latest annual report
- 10-K · Mar 12, 2026
Companies similar to Candel Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATTOAttovia Therapeutics Inc. | 16.21 | -0.61% | $740.01M | vs CADL |
| SLDBSolid Biosciences Inc. | 6.87 | +0.73% | $736.64M | vs CADL |
| FDMT4D Molecular Therapeutics Inc. | 13.33 | +4.96% | $736.41M | vs CADL |
| PRMEPrime Medicine Inc. | 3.99 | +11.45% | $723.69M | vs CADL |
| PROKProKidney Corp. Class A | 1.74 | +4.82% | $694.58M | vs CADL |
| AURAAura Biosciences Inc. | 6.54 | +0.54% | $678.23M | vs CADL |
| SANASana Biotechnology Inc. | 2.79 | 0.00% | $835.22M | vs CADL |
| SLBTSL Science Holding Limited | 1.51 | -0.66% | $846.75M | vs CADL |